<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE302nnn/GSE302321/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302321</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers - ChIP-seq data from genetic disruption of EZH2</name><description>TEA/TEF-domain [TEAD] inhibitors are being evaluated in clinical trials for cancers with alterations in the Hippo pathway including mesothelioma. We recently developed and showcased the potency of TEAD palmitoylation inhibitors MYF-03-69 and MYF-03-176 in mesothelioma cell lines. However, TEAD inhibition results in cell cycle arrest in cell line models with Hippo pathway alterations without inducing cell death, potentially limiting their long-term clinical efficacy. Using a genome-wide CRISPR/Cas9 screen, we identified EZH2 as a critical modulator of the cellular response to TEAD inhibition. Compared to single agent treatments, EZH2i/TEADi robustly triggered apoptosis and suppressed the growth of Hippo-mutated cells in vitro and in vivo. Mechanistically, EZH2i/TEADi-treated cells exhibited heightened activation of tumor-intrinsic innate immune signaling which resulted in DNA damage and subsequent apoptosis. Taken together, we propose this novel combinatorial strategy as a potential approach to enhancing the anti-tumor efficacy of single agent TEAD targeting therapies in Hippo pathway altered tumors. This GEO accession includes the data series associated with ChIP-seq derived from genetic disruption of EZH2.</description><dates><publication>2026/07/17</publication></dates><accession>GSE302321</accession><cross_references><GSM>GSM9101839</GSM><GSM>GSM9101836</GSM><GSM>GSM9101858</GSM><GSM>GSM9101857</GSM><GSM>GSM9101835</GSM><GSM>GSM9101838</GSM><GSM>GSM9101859</GSM><GSM>GSM9101837</GSM><GSM>GSM9101843</GSM><GSM>GSM9101865</GSM><GSM>GSM9101864</GSM><GSM>GSM9101842</GSM><GSM>GSM9101867</GSM><GSM>GSM9101845</GSM><GSM>GSM9101866</GSM><GSM>GSM9101844</GSM><GSM>GSM9101861</GSM><GSM>GSM9101860</GSM><GSM>GSM9101863</GSM><GSM>GSM9101841</GSM><GSM>GSM9101840</GSM><GSM>GSM9101862</GSM><GSM>GSM9101829</GSM><GSM>GSM9101828</GSM><GSM>GSM9101847</GSM><GSM>GSM9101846</GSM><GSM>GSM9101868</GSM><GSM>GSM9101849</GSM><GSM>GSM9101848</GSM><GSM>GSM9101832</GSM><GSM>GSM9101854</GSM><GSM>GSM9101831</GSM><GSM>GSM9101853</GSM><GSM>GSM9101856</GSM><GSM>GSM9101834</GSM><GSM>GSM9101833</GSM><GSM>GSM9101855</GSM><GSM>GSM9101850</GSM><GSM>GSM9101852</GSM><GSM>GSM9101830</GSM><GSM>GSM9101851</GSM><GPL>24676</GPL><GSE>302321</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>